幽门螺杆菌与炎症性肠病关系的研究进展

Abstract
Figure/Table
References (33)
Related Citation (15)

Download: PDF (472 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Inflammatory bowel disease (IBD) is a chronic inflammatory disease affecting intestinal tract. Existing researches suggest that environment, genetics, immunity and infection may be involved in its pathogenesis. Helicobacter pylori (H.pylori) is a common human pathogen, which is associated with a variety of gastric and extra-gastric diseases. In recent years, a lot of data show a negative correlation between them, and studies find that this association may be related to the immune regulation characteristics of H.pylori or other confounding factors such as antibiotics, sulfasalazine and environment. In addition, there are cases of newly diagnosed IBD after the eradication of H.pylori and it may trigger Crohn disease by affecting the balance between Th1 and Th2 immune response. The association between H.pylori and IBD as well as the mechanism are disscussed in this paper, and the article also reviews the development of IBD after the eradication of H.pylori.

Key words： Helicobacter pylori Inflammatory bowel disease Association Immune

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHENG Yi′an TAN Shiyun LI Ming

Cite this article:

CHENG Yi′an TAN Shiyun LI Ming. The research progress of association between Helicobacter pylori and inflammatory bowel disease[J]. 中国医药导报, 2018, 15(21): 27-30.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I21/27

[1] Legaki E，Gazouli M. Influence of environmental factors in the development of inflammatory bowel diseases [J]. World J Gastrointest Pharmacol Ther，2016，7（1）：112-125.
[2] Hooi JKY，Lai WY，Ng WK，et al. Global Prevalence of Helicobacter pylori Infection： Systematic Review and Meta-analysis [J]. Gastroenterology，2017，153（2）：420-429.
[3] El-Omar E，Penman I，Cruikshank G，et al. Low prevalence of Helicobacter pylori in inflammatory bowel disease： association with sulphasalazine [J]. Gut，1994，35（10）：1385-1388.
[4] Pearce CB，Duncan HD，Timmis L，et al. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease [J]. Eur J Gastroenterol Hepatol，2000，12（4）：439-443.
[5] Piodi LP，Bardella M，Rocchia C，et al. Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease [J]. J Clin Gastroenterol，2003，36（1）：22-25.
[6] Wu XW，Ji HZ，Yang MF，et al. Helicobacter pylori infection and inflammatory bowel disease in Asians： A meta-analysis [J]. World J Gastroenterol，2015，21（15）：4750-4756.
[7] Lahat A，Kopylov U，Neuman S，et al. Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn′s disease [J]. BMC Gastroenterol，2017，17（1）：27-32.
[8] Roka K，Roubani A，Stefanaki K，et al. The Prevalence of Helicobacter pylori Gastritis in Newly Diagnosed Children with Inflammatory Bowel Disease [J]. Helicobacter，2014， 19（5）：400-405.
[9] Castano-Rodríguez N，Kaakoush NO，Lee WS，et al. Dual role of Helicobacter and Campylobacter species in IBD： a systematic review and meta-analysis [J]. Gut，2017，66（2）：235-249.
[10] Rokkas T，Gisbert JP，Niv Y，et al. The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis [J]. United European Gastroenterol J，2015，3（6）：539-550.
[11] Ananthakrishnan AN. Epidemiology and risk factors for IBD [J]. Nat Rev Gastroenterol Hepatol，2015，12（4）：205-217.
[12] Peleteiro B，Bastos A，Ferro A，et al. Prevalence of Helicobacter pylori infection worldwide： a systematic review of studies with national coverage [J]. Dig Dis Sci，2014， 59（8）：1698-1709.
[13] Higgins PD，Johnson LA，Luther J，et al. Prior H. pylori infection ameliorates S. typhimurium induced colitis： mucosal crosstalk between stomach and distal intestine [J]. Inflamm Bowel Dis，2011，17（6）：1398-1408.
[14] Wu J，Lin K，Zeng JQ，et al. Role of DC-SIGN in Helicobacter pylori infection of gastrointestinal cells [J]. Front Biosci，2014，19（5）：825-834.
[15] Luther J，Owyang SY，Takeuchi T，et al. Helicobacter pylori DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitis [J]. Gut，2011，60（11）：1479-1486.
[16] Engler DB，Leonardi I，Hartung ML，et al. Helicobacter pylori-specific protection against inflammatory bowel disease requires the NLRP3 inflammasome and IL-18 [J]. Inflamm Bowel Dis，2015，21（4）：854-861.
[17] Codolo G，Mazzi P，Amedei A，et al. The neutrophil-activating protein of Helicobacter pylori， down-modulates Th2 inflammation in ovalbumin-induced allergic asthma [J]. Cell Microbiol，2008，10（11）：2355-2363.
[18] 林焕建，王启仪，刘颖，等.幽门螺杆菌过氧化氢酶预防大鼠溃疡性结肠炎的实验研究[J].热带医学杂志，2007， 7（7）：626-628.
[19] Sun X，Zhang M，El-Zataari M，et al. TLR2 mediates Helicobacter pylori-induced tolerogenic immune response in mice [J]. Plos One，2013，8（9）：e74595.
[20] Koch KN，Müller A. Helicobacter pylori activates the TLR2/NLRP3/caspase-1/IL-18 axis to induce regulatory T-cells， establish persistent infection and promote tolerance to allergens [J]. Gut Microbes，2015，6（6）：382-387.
[21] Pachathundikandi SK，Müller A，Backert S. Inflammasome activation by helicobacter pylori and its implications for persistence and immunity [J]. Curr Top Microbiol Immunol，2016，397：117-131.
[22] Kyburz A，Müller A. Helicobacter pylori and extragastric diseases [J]. Curr Top Microbiol Immunol，2017，400：325-347.
[23] Arnold IC，Hitzler I，Müller A. The Immunomodulatory properties of helicobacter pylori confer protection against allergic and chronic inflammatory disorders [J]. Front Cell Infect Microbiol，2012，2（10）：10.
[24] Kronsteiner B，Bassaganya-Riera J，Philipson C，et al. Systems-wide analyses of mucosal immune responses to Helicobacter pylori at the interface between pathogenicity and symbiosis [J]. Gut Microbes，2016，7（1）：3-21.
[25] Song MJ，Park DI，Hwang SJ，et al. The prevalence of Helicobacter pylori infection in Korean patients with inflammatory bowel disease， a multicenter study [J]. Korean J Gastroenterol，2009，53（6）：341-347.
[26] Triantafillidis JK，Gikas A，Merikas E. Treatment of inflammatory bowel disease patients with anti-TNF-α factors and immunosuppressives does not influence the prevalence of Helicobacter pylori， infection [J]. Indian J Gastroenterol，2014，33（4）：383-384.
[27] Papamichael K，Konstantopoulos P，Mantzaris GJ. Helicobacter pylori infection and inflammatory bowel disease： is there a link? [J]. World J Gastroenterol，2014， 20（21）：6374-6385.
[28] Kwj VDS，Amini M，Peters V，et al. Inflammatory Bowel Diseases： Review of Known Environmental Protective and Risk Factors Involved [J]. Inflamm Bowel Dis，2017， 23（9）：1499-1509.
[29] Bartels LE，Jepsen P，Christensen LA，et al. Diagnosis of helicobacter pylori infection is associated with lower prevalence and subsequent incidence of crohn′s disease [J]. J Crohns Colitis，2016，10（4）：443-448.
[30] Tursi，Antonio. Onset of Crohn′s disease after Helicobacter pylori eradication [J]. Inflamm Bowel Dis，2006，12（10）：1008-1009.
[31] Murad HA. Does Helicobacter pylori eradication therapy trigger or protect against Crohn′s disease? [J]. Acta Gastroenterol Belg，2016，79（3）：349-354.
[32] Chiba M，Tsuji T，Takahashi K，et al. Onset of Ulcerative Colitis after Helicobacter pylori Eradication Therapy： A Case Report [J]. Perm J，2016，20（2）：e115-e118.
[33] Thia KT，Loftus EV，Sandborn WJ，et al. An Update on the Epidemiology of Inflammatory Bowel Disease in Asia [J]. Am J Gastroenterol，2008，103（12）：3167-3182.